. We identified two genes significantly associated with CLL (q ⩽ 0.05): CDK1 and ATM. CDK1, a gene that encodes a cyclindependent kinase critical for cell division, was significantly enriched for rare, non-synonymous germline variants in CLL cases versus controls (P = 5.75 × 10 − 7 , Table 1 ). One recurrent missense variant, CDK1 p.R59C (rs8755), was observed in five cases and 10 controls ( Supplementary Table S3 ). This missense variant lies in the CDK1 kinase domain (Supplementary Figure S3 ) and is predicted to be possibly damaging by the PolyPhen2 prediction tool, 2 suggesting that the variant may affect protein function.
The second significant gene we identified was ATM (P = 1.43 × 10 − 6 , Table 1 ), a well-known tumor suppressor gene on chromosome 11q. One of the most enriched recurrent variants is L2307F (2.3% cases, odds ratio (OR) = 10.1, 4.9-20.7). Interestingly, L2307F has been previously reported in two CLL cases and a breast cancer case, the latter segregating in a family also affected with hematologic malignancy. 3, 4 The L2307F variant lies in the FAT domain of the ATM protein ( Figure 1a ) and is predicted to be probably damaging by PolyPhen2. Subsequent targeted sequencing using Sequenom technology in an independent set of 149 CLL cases revealed a similar frequency of 2.01% (3 out of 149) for the L2307F variant. In 27 cases with available RNASeq data, expression of the rare germline ATM variant was confirmed, and in all but one case, the alternate allele fractions in RNA transcripts were consistent with those in germline genomic DNA ( Supplementary Table S4 ).
The majority of the recurrent variants observed in ATM were non-synonymous missense variants ( Supplementary Table S6 ) in contrast to the predominantly loss-of-function alleles seen in ataxia-telangiectasia, a hereditary disorder associated with increased risk of leukemias and lymphomas. Analysis of the frequency-weighted distribution of PolyPhen2 scores across these missense variants revealed a significant shift toward more damaging scores in the cases versus controls (P = 0.0038, onesided Kolmogorov-Smirnov test; Supplementary Figure S4 ). These observations are consistent with recent reports of the potential role of germline missense variants in cancer heritability. 5, 6 In fact, 22 of the rare missense ATM variants we identified in CLL cases were also associated with breast cancer risk in a meta-analysis of breast cancer studies. 7 As an extension to our initial findings, we studied two additional cohorts of CLL cases (n = 106 exomes and n = 24 genomes). We combined these additional cases with our 516 original cases and compared against our original control cohort. This expanded joint analysis approach has been shown to consistently improve the statistical power for detecting genetic associations. 8 We found ATM to be the top hit in this combined analysis (P = 1.04 × 10 − 8 , Table 1 , Supplementary Table S5 ). ATM variants are summarized in Figure 1b and Supplementary Table S6 , while patient characteristics by ATM germline status are summarized in Supplementary  Table S7 . For CDK1, no additional rare variants were found in the extension cohort and hence its significance dropped below our significance threshold (q = 0.107, Table 1 , Supplementary Table  S8 ). Patient characteristics by CDK1 germline status are summarized in Supplementary Table S9 . The classical model of tumor suppressor inactivation involves the loss of both wild-type alleles of the tumor suppressor gene. In CLL, ATM is frequently lost through somatic deletion of the chromosome 11q region that spans the ATM locus 9 and through inactivating somatic mutations. 10, 11 We observed an enrichment of these somatic 'second hits' in patient samples harboring rare ATM germline variants. Among the 112 patients in the discovery cohort with ATM germline variants, we found 23 with somatic ATM mutations, 29 with 11q deletions and 2 with copy-neutral loss of heterozygosity (LOH) in the ATM locus ( Figure 1c ). The presence of a germline ATM variant was significantly associated with the occurrence of an ATM somatic mutation (OR = 1.79, 95% CI 0.98-3.16; P = 0.047, two-tailed Fisher exact test), as well as with LOH, either copy-neutral or via 11q deletion (OR = 1.68, 95% CI 0.98-2.82; P = 0.042, two-tailed Fisher exact test). Overall, the presence of a rare germline ATM variant was significantly associated with the presence of at least one of these somatic events (OR = 2.17, 95% CI 1.35-3.48; P = 9.1 × 10 − 4 , two-tailed Fisher exact test). The association remained significant in the extension cohort (OR = 1.74, 95% CI 1.16-2.60; P = 5.5 × 10 − 3 , two-tailed Fisher exact test). The observation that patients with rare coding germline variants in ATM were significantly more likely to harbor a second inactivating somatic lesion in ATM suggests that rare germline variants in ATM behave as tumor suppressor alleles.
To test further whether the rare germline ATM variants are likely to be functional, we examined which ATM allele is lost when 11q is deleted. If the variants had no effect on the development of CLL, we would expect an equal likelihood of their loss or retention in 11q deleted cases. Strikingly, we found that patients with rare germline ATM variants who acquired an 11q deletion more often lost the wild-type ATM allele. Specifically, 80% carried only the rare variant germline allele in their tumor samples (16 out of 20 with clonal or near-clonal del(11q). This rate of wild-type allele loss is significantly greater than expected by chance (P = 0.012, twotailed binomial test). Furthermore, in the four cases that lost the variant allele, none of the variants had probably damaging PolyPhen2 scores, suggesting that their effect on protein function was less severe. These results suggest that many rare germline ATM alleles may confer selective advantage to malignant B-cells.
Given the association of somatic 11q deletion 9 or ATM mutation 12 with worse clinical outcomes in CLL, we investigated whether the presence of a rare germline variant in ATM would be associated with worse clinical outcomes. In a Cox regression analysis adjusting for treatment arm, somatic del(11q), but not germline ATM variant, was a significant predictor of outcome (Supplementary Tables S10 and S11, Supplementary Figure S5 ). When we added two other CLL prognostic factors, del(17p) and IGHV status, to the Cox regression analysis ( Supplementary Table  S12 ), del(11q) was no longer significantly associated with progression-free survival. We also investigated the effect of a rare germline ATM variant and/or 11q deletion on overall survival, and saw no effect, including in a Cox regression analysis adjusting for treatment arm ( Supplementary Table S13 , Supplementary Figure S6 ).
Taken together, our results show that rare, protein-coding germline variants in ATM are frequent events in CLL, with ATM behaving as a classic tumor suppressor gene, showing preferential somatic loss of the wild-type allele. Although previous research has hinted at a role for specific alleles of ATM in CLL risk, these studies either involved relatively small sample sizes, resulting in low statistical power, or were targeted approaches that did not evaluate the entire ATM gene or did not evaluate ATM against other potential risk genes in an unbiased, exome-wide manner. [13] [14] [15] In contrast, we have applied consistent technical processing to a large cohort of jointly called, ethnically matched CLL and normal population controls, with a focus on rare coding variants. This, along with careful quality control, variant filtering and accounting for population substructure in an unbiased, exome-wide association analysis, allowed us to identify ATM as a CLL risk gene.
Because CLL predominantly affects individuals of European descent, we chose to focus our study on patients of European ethnicity. We expect, however, that further studies examining patients of different ethnic backgrounds may uncover additional germline risk genes not detectable in the European study cohort. Indeed, the presence of residual population substructure within the cohort of European subjects in this study suggests that there may be germline predisposition genes affecting different European subpopulations that we have not yet identified. Another area requiring further exploration is the search for germline risk factors in familial CLL cases. Our study included many patients for whom the familial or sporadic disease status was not available (n = 387), and among those with known status, most were sporadic or without living affected or available relatives (n = 195). Larger studies of whole exomes and whole genomes with a focus on familial cases and underrepresented ethnic populations will be needed to further increase power to detect additional risk genes and alleles for CLL. The approach we describe here, combining rare variant association with somatic sequencing analysis, can be applied to any type of heritable cancer and holds great promise for identifying new germline cancer predisposition alleles as progressively larger cohorts of germline cancer samples are sequenced.
Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML Leukemia (2017) 31, 2247-2251; doi:10.1038/leu.2017.217
Myelodysplastic syndromes (MDS) represent clonal disorders of hematopoietic stem cells resulting in peripheral blood cytopenias and a propensity to develop acute myeloid leukemia (AML). Therapy-associated MDS (t-MDS) comprise roughly 10% of all MDS cases as a result of intensive chemotherapy of solid tumors and certain hematological malignancies, 1 for example, after curative treatment for de novo acute promyelocytic leukemia (APL). [2] [3] [4] Furthermore, only sporadic reports exist for patients with other subgroups of de novo AML. [5] [6] [7] [8] [9] [10] Here we describe five patients initially diagnosed with nucleophosmin 1 (NPM1 type A) -mutated de novo AML, whom all developed t-MDS (MDS with multilineage dysplasia, MDS-MLD, n = 3; MDS with excess blasts, MDS-EB1 n = 2) after a long latency (median 46 months, range: 28-92). All patients underwent conventional double induction chemotherapy using standard anthracycline/ cytarabine combinations according to the protocols of the Study Alliance Leukemia (SAL) as shown in Table 1 . All patients had been followed closely for MRD after the end of conventional chemotherapy. In fact, at the time of onset of t-MDS all patients still displayed molecular CR based on NPM1 MRD assessment (NPM1 mut / ABLo0.001%) pointing towards a therapy-related secondary malignancy. Consequently, we wanted to evaluate and better understand the clonal evolution of somatic mutations in diagnosis and follow-up samples of these patients.
The median age at primary AML diagnosis was 58 years (range: 47-74). Four patients had AML with normal karyotype and one patient (UPN3) had trisomy 4 while two patients (UPN2,3) displayed a chromosome 7 abnormality at the time of t-MDS (Table 1 ). This is in line with the literature, where chromosome 7 abnormalities have been clearly linked to occur secondary after exposure to chemotherapeutic agents such as alkylating drugs. Nevertheless, since karyotype was normal in the majority of patients we next sought to identify and compare molecular abnormalities between AML and t-MDS phenotypes.
Extended targeted AML panel sequencing (Supplementary Information and Supplementary Tables S1 and S2) with median coverage of 9254x revealed recurrent mutations apart from NPM1 of the following genes at the time of AML diagnosis: DNMT3A (n = 4), TET2 (n = 2), FLT3-ITD (n = 2), IDH1/2 (n = 1 each), KIT and KRAS (n = 1 each). While NPM1 mutation was not detectable in all t-MDS cases, at the time of t-MDS diagnosis patients acquired new mutations (UPN1,2,5: DNMT3A; UPN4: U2AF1; UPN5: GATA2, RUNX1), lost mutations (UPN1,3: FLT3-ITD; UPN4: TET2; UPN5: KIT, KRAS) and some remained still detectable (UPN1: IDH1; UPN2: DNMT3A, IDH2; UPN3: DNMT3A, TET2; UPN4: DNMT3A; Table 1 , Figure 1 and Supplementary Table S3 ). Tracking of VAF for DNMT3A (c.2473G4A; UPN1), U2AF1 (c.101C4A, UPN4) and DNMT3A (c.2644C4T; UPN5) was additionally performed by targeted re-sequencing on the Ion PGM System (ThermoFisher Scientific, Darmstadt, Germany) platform in first diagnosis AML samples with a higher sensitivity ( Supplementary Information and  Supplementary Tables S2 and S3 ). No MLL rearrangement was found in any case (data not shown).
We next analyzed patient´s individual variant allele frequencies (VAFs) of mutations during the course of time. All patients still continued to have a clonal pre-leukemic hematopoiesis even during complete molecular remission (NPM1), albeit with two different patterns. Even though a decline of VAFs during AML therapy indicates an initial susceptibility to treatment, preleukemic clones increased later on. Briefly, in patients UPN1-4 pre-leukemic clones harboring mutant IDH1/2, DNMT3A or TET2 were present prior to treatment, were not eradicated by consolidation chemotherapy, rather persisted and/or expanded during the time of t-MDS development (Figure 1 , Supplementary  Table S3 ). In addition, patients acquired new somatic alterations typically found in MDS/t-MDS (for example, del(7q), U2AF1 and DNMT3A 11,12 ) a median of 28 months after completion of AML Accepted article preview online 10 July 2017; advance online publication, 4 August 2017
